Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life

OBJECTIVE: The aim of this study was to determine if direct-acting antiviral (DAA) treatment with daclatasvir (DCV) plus asunaprevir (ASV) for 24 weeks influenced the health-related quality of life (HRQOL) at 12 and 24 weeks after treatment initiation [end of treatment (EOT)]. METHODS: This was a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakubo, Megumi, Eguchi, Yuichiro, Okada, Michiaki, Iwane, Shinji, Oeda, Satoshi, Otsuka, Taiga, Nakashita, Syunya, Araki, Norimasa, Koga, Akemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096027/
https://www.ncbi.nlm.nih.gov/pubmed/29526929
http://dx.doi.org/10.2169/internalmedicine.0091-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096027/
https://www.ncbi.nlm.nih.gov/pubmed/29526929
http://dx.doi.org/10.2169/internalmedicine.0091-17

Ejemplares similares